JP2021523717A5 - - Google Patents

Info

Publication number
JP2021523717A5
JP2021523717A5 JP2020564104A JP2020564104A JP2021523717A5 JP 2021523717 A5 JP2021523717 A5 JP 2021523717A5 JP 2020564104 A JP2020564104 A JP 2020564104A JP 2020564104 A JP2020564104 A JP 2020564104A JP 2021523717 A5 JP2021523717 A5 JP 2021523717A5
Authority
JP
Japan
Prior art keywords
cells
immune cells
population
modified immune
population according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020564104A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523717A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/031296 external-priority patent/WO2019221991A1/en
Publication of JP2021523717A publication Critical patent/JP2021523717A/ja
Publication of JP2021523717A5 publication Critical patent/JP2021523717A5/ja
Pending legal-status Critical Current

Links

JP2020564104A 2018-05-14 2019-05-08 代謝、生存、および機能を促進するための免疫細胞におけるarid5b発現の操縦 Pending JP2021523717A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862670962P 2018-05-14 2018-05-14
US62/670,962 2018-05-14
PCT/US2019/031296 WO2019221991A1 (en) 2018-05-14 2019-05-08 Manipulating arid5b expression in immune cells to promote metabolism, survival, and function

Publications (2)

Publication Number Publication Date
JP2021523717A JP2021523717A (ja) 2021-09-09
JP2021523717A5 true JP2021523717A5 (cg-RX-API-DMAC7.html) 2022-05-17

Family

ID=68540927

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020564104A Pending JP2021523717A (ja) 2018-05-14 2019-05-08 代謝、生存、および機能を促進するための免疫細胞におけるarid5b発現の操縦

Country Status (7)

Country Link
US (1) US12109236B2 (cg-RX-API-DMAC7.html)
EP (1) EP3793574A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021523717A (cg-RX-API-DMAC7.html)
CN (1) CN112888446A (cg-RX-API-DMAC7.html)
AU (1) AU2019269318A1 (cg-RX-API-DMAC7.html)
CA (1) CA3100312A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019221991A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7793517B2 (ja) * 2019-11-28 2026-01-05 アムニオティクス・アーベー ソース細胞から決定的造血細胞を生成する方法
CN111733154B (zh) * 2020-04-30 2022-11-04 和也健康科技有限公司 磁场处理的免疫细胞及其用途
KR20230042671A (ko) * 2020-05-28 2023-03-29 바이오마그네틱 솔루션스 엘엘씨 단일 항체를 이용한 나이브 t 및 b 세포의 음성 선택을 위한 조성물 및 방법
EP4419541A4 (en) * 2021-10-21 2025-12-17 Univ Texas METHOD FOR PRODUCING THERAPEUTIC IMMUNE CELLS WITH IMPROVED METABOLIC FITNESS AND COMPOSITIONS THEREOFUL

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837492A (en) 1995-12-18 1998-11-17 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
US6448717B1 (en) 2000-07-17 2002-09-10 Micron Technology, Inc. Method and apparatuses for providing uniform electron beams from field emission displays
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
EP3349770A1 (en) * 2015-09-14 2018-07-25 Regents of the University of Minnesota Nk cells exhibiting an adaptive phenotype and methods for preparing and for using
US20180371052A1 (en) 2015-12-22 2018-12-27 Icell Gene Therapeutics Llc Chimeric antigen receptors and enhancement of anti-tumor activity
EP3452580B1 (en) 2016-05-02 2023-08-16 Cerus Corporation Compositions and methods for improved nk cell therapies

Similar Documents

Publication Publication Date Title
Galland et al. Mesenchymal stromal cells in cancer: a review of their immunomodulatory functions and dual effects on tumor progression
Gao et al. Interleukin-10 genetically modified clinical-grade mesenchymal stromal cells markedly reinforced functional recovery after spinal cord injury via directing alternative activation of macrophages
Bianchi et al. Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells
Martinez et al. Overexpression of hypoxia-inducible factor 1 alpha improves immunomodulation by dental mesenchymal stem cells
Zhu et al. Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo
JP6992809B2 (ja) 免疫疾患の治療のための高効能幹細胞の選別方法
Marigo et al. The immunomodulatory properties of mesenchymal stem cells
Ozawa et al. Cell and gene therapy using mesenchymal stem cells (MSCs)
Janssens et al. Leukemia inhibitory factor tips the immune balance towards regulatory T cells in multiple sclerosis
Huang et al. Cellular crosstalk in the bone marrow niche
Papait et al. The multifaceted roles of MSCs in the tumor microenvironment: interactions with immune cells and exploitation for therapy
Song et al. Human mesenchymal stem cells derived from umbilical cord and bone marrow exert immunomodulatory effects in different mechanisms
Ye et al. Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics
Tang et al. The role of mesenchymal stem cells in cancer and prospects for their use in cancer therapeutics
Vladimirovna et al. Mesenchymal stem cells and myeloid derived suppressor cells: common traits in immune regulation
Yang et al. Umbilical cord blood-derived mesenchymal stromal cells promote myeloid-derived suppressor cell proliferation by secreting HLA-G to reduce acute graft-versus-host disease after hematopoietic stem cell transplantation
Cifù et al. The exposure to osteoarthritic synovial fluid enhances the immunomodulatory profile of adipose mesenchymal stem cell secretome
Ding et al. The monocytes that repopulate in mice after cyclophosphamide treatment acquire a neutrophil precursor gene signature and immunosuppressive activity
Andrlova et al. An unconventional view of T cell reconstitution after allogeneic hematopoietic cell transplantation
US20220381772A1 (en) Systems and methods for evaluating nk cells
JP2021512164A (ja) トランスフォーミング増殖因子ベータ抵抗性ナチュラルキラー細胞
JP2021523717A (ja) 代謝、生存、および機能を促進するための免疫細胞におけるarid5b発現の操縦
Hasegawa et al. Effective-mononuclear cell (E-MNC) therapy alleviates salivary gland damage by suppressing lymphocyte infiltration in Sjögren-like disease
Wang et al. Update on cancer related issues of mesenchymal stem cell-based therapies
Pyaram et al. Advances in NKT cell immunotherapy for glioblastoma